NCT05749380View on ClinicalTrials.gov

Pharmacokinetics and Safety of AmBisome and DKF-5122

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Invasive Fungal InfectionsNeutropenic Fever
Interventions
DRUG

AmBisome

Reference, dose of 3 mg/kg.

DRUG

DKF-5122

Test, dose of 3 mg/kg

Trial Locations (1)

06591

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Dongkook Pharmaceutical Co., Ltd.

INDUSTRY

NCT05749380 - Pharmacokinetics and Safety of AmBisome and DKF-5122 | Biotech Hunter | Biotech Hunter